ReviewBone marrow transplantation2009
Experimental basis of cord blood transplantation.
Review in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Optimizing autologous cell grafts to improve stem cell gene therapy.Experimental hematology · 2016Review
- Enhancing the efficacy of engraftment of cord blood for hematopoietic cell transplantation.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2016Review
- Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT.Blood cancer journal · 2014Article
- Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns.Stem cells and development · 2013Review
- The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression.Immunologic research · 2013Review
- Developmental changes in hematopoietic stem cell properties.Experimental & molecular medicine · 2013Review
- Review
- Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic?Bone marrow transplantation · 2012Review
- Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function.Annals of the New York Academy of Sciences · 2012Review
- Ex vivo expansion of umbilical cord blood: where are we?International journal of hematology · 2012Review
- In vivo chemical screening for modulators of hematopoiesis and hematological diseases.Advances in hematology · 2012Article
- Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models.Cell stem cell · 2011Article
- Insights into the biology of cord blood stem/progenitor cells.Cell proliferation · 2011Review
- Risk factors and options to improve engraftment in unrelated cord blood transplantation.Stem cells international · 2011Article
- Article
- Placenta as a newly identified source of hematopoietic stem cells.Current opinion in hematology · 2010Review
- Advances in cord blood transplants in adults.F1000 medicine reports · 2010Article
- Umbilical cord transplantation: epilogue.Seminars in hematology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efforts are needed to enhance the efficacy of cord blood (CB) transplantation. Laboratory information set the stage for the first and subsequent CB transplants, and will be instrumental in continuing to advance the field. This paper offers a brief understanding of the current state of hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) biology, a look back at laboratory studies leading to the first CB transplants, and a discussion of the possible means to enhance CB transplantation. Results show that physical recovery of greater numbers of HPCs is possible after CB is collected by perfusing the placenta, but how realistic this procedure is for collection of CB to be banked is open to question. We also show that the chemokine stromal cell-derived factor-1/CXCL12 can enhance the ex vivo expansion of CB HPCs beyond that of the combination of SCF, Flt3-ligand and TPO. Advances in cytokine and stromal cell biology, and in intracellular signals mediating the effects of cytokines/stromal cells should be considered in the context of future efforts to enhance functional activities of donor CB HSCs and HPCs and the microenvironmental niche of the recipient, which is required for acceptance and nurturing these HSCs/HPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.